Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8240581 | 0.83 | MAPK1 (0.37) | MAPK1KDM4EHSD17B10MAPTPOLB | |
| SCHEMBL8273078 | 0.82 | MAPK1 (0.36) | MAPK1KDM4EHSD17B10MAPTPOLB | |
| SCHEMBL8130016 | 0.79 | KDM4E (0.41) | MAPK1KDM4EHSD17B10MAPTPOLB | |
| SCHEMBL14092796 | 0.78 | PRKCI (0.30) | — | |
| SCHEMBL13409400 | 0.77 | ELANE (0.35) | MAPK1KDM4EHSD17B10MAPTPOLB | |
| SCHEMBL13409402 | 0.69 | ADORA2A (0.40) | ELANE | |
| SCHEMBL13409401 | 0.69 | ELANE (0.34) | MAPTELANEALDH1A1 | |
| SCHEMBL13409407 | 0.68 | ELANE (0.33) | KDM4EELANEALDH1A1 | |
| SCHEMBL13409408 | 0.68 | TRPV1 (0.39) | KDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL13409388 | 0.68 | L3MBTL1 (0.45) | MAPK1KDM4EMAPTELANETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705146-B2 | Hepatitis C inhibitor peptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-27 | — | — | US | disclosed |
| US-20080200497-A1 | Hepatitis C Inhibitor Peptide Analogs | BAILEY MURRAY D | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200497-A1 | Hepatitis C Inhibitor Peptide Analogs | HAVCR2, ZC3HAV1, CTSC | MAPK1 1704/4885KDM4E 1807/4885HSD17B10 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.